Orchestra BioMed OBIO 深 滬
已收盤 11-06 16:00:00 美东时间
5.68
+0.060
+1.07%
華盛通- 最 高6.04
- 今 開5.135
- 成交量 174.14万股
- 最 低 5.10
- 昨 收 5.62
- 總市值 3.41亿
- 52周最高 6.50
- 市盈率 靜 --
- 換手率 2.90%
- 52周最低 3.46
- 委 比 82.54%
- 總股本 6010.50万
- 歷史最高 23.39
- 量 比 6.14
- 振 幅 16.73%
- 歷史最低 2.20
- 每 手 1
- 風險率 0.71%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Orchestra BioMed shares are trading lower after the company announced a proposed public offering.
Orchestra BioMed shares are trading lower after the company announced a proposed public offering.
11-06 06:09
Orchestra BioMed Announces Pricing of Public Offering
Orchestra BioMed Holdings, Inc. announced the pricing of a public offering of 15,000,000 shares of common stock at $5.00 per share, with an additional 2,250,000 shares available under the underwriters' option. The gross proceeds are expected to be $75.0 million, to be used for funding the AVIM Therapy and Virtue SAB programs, clinical trials, and other product development. The offering is expected to close on November 9, 2026, with Piper Sandler ...
11-06 03:42
Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB
Orchestra BioMed will host an R&D Day on November 12, 2026, in New York City and via live webcast. The event will feature discussions on unmet patient needs, the BACKBEAT and Virtue pivotal trials, and upcoming milestones. Key cardiologists will address hypertension in pacemaker patients and restenosis in coronary stent interventions. The agenda includes sessions on AVIM Therapy, Virtue SAB, and Q&A, led by company executives and medical experts....
10-22 12:30
Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy
Orchestra BioMed announced the completion of enrollment in the BACKBEAT Trial, surpassing the target of 316 randomized patients with 330 participants across 13 countries. The trial evaluates AVIM Therapy for uncontrolled hypertension in pacemaker patients. Primary endpoint data is expected in Q2 2027 for potential late-breaking presentation and future FDA submissions. AVIM Therapy aims to lower blood pressure through atrioventricular interval mod...
10-01 12:00
美股大行评级 | 齐声看好医药股！礼来、强生、默沙东目标价均获上调；小摩大幅上调Meta目标价至820美元
今日重点评级关注：康托·菲茨杰拉德：维持SOL Strategies"超配"评级，目标价从2.8美元升至6.2美元；康托·菲茨杰拉德：维持Sui Group Holdings"超配"评级，目标价从1.7美元升至3.4美元
09-11 14:30
Wealthfront, Orchestra Biomed, AeroVironment And Other Big Stocks Moving Higher On Thursday
U.S. stocks were lower, with the Dow Jones index falling around 250 points on Thursday. Shares of Wealthfront Corp (NASDAQ:WLTH) rose sharply during Thursday’s session following better-than-expected second-quarter results. Wealthfront reported quarterly earnings of 10 cents per share which beat the ...
09-10 22:02
This Meta Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Keefe, Bruyette & Woods analyst Wood Lay upgraded Simmons First National Corp (NASDAQ:SFNC) from ...
09-10 20:53
BTIG Upgrades Orchestra BioMed Hldgs to Buy, Announces $10 Price Target
BTIG analyst Marie Thibault upgrades Orchestra BioMed Hldgs (NASDAQ:OBIO) from Neutral to Buy and announces $10 price target.
09-10 17:56
Orchestra BioMed Highlights Pivotal Cardiovascular Program Progress
An announcement from Orchestra BioMed Holdings ( ($OBIO) ) is now available. In...
09-08 21:54
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Orchestra BioMed Holdings, Inc. granted stock options to purchase 133,000 shares of its common stock to seven newly hired employees on September 1, 2026, under its 2025 New Hire Inducement Plan. The stock options will vest over a four-year period. The company, which accelerates high-impact biomedical technologies through partnerships with global medical device leaders, is currently developing two flagship products: AVIM Therapy for hypertension a...
09-02 20:05
